ODTX ODTX
Company Profile ↓Company Overview
ODTX (ODTX) is a publicly traded company listed on with a market capitalization of $985.47M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 30.4%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $2.98M (-33.5% YoY); net profit $-148.65M.
- Trailing 12 Months Year-on-year growth — revenue -33.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -33.45% |
Stock Price Performance
| 1 Year: | +27.22% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +31.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)66.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.4%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 1.75M | 1.92M | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 38.88M | 46.73M | 39.67M |
| Operating Income | -37.12M | -44.81M | -39.67M |
| EBITDA | -34.59M | -36.99M | -37.02M |
| Interest Expense | 4.00K | 2.00K | 10.00K |
| Pretax Income | -35.88M | -38.30M | -38.20M |
| Tax Provision | 47.00K | 140.00K | 63.00K |
| Net Income | -35.93M | -38.44M | -38.26M |
| Diluted EPS | - | -1.39 | -0.81 |
| R&D Expense | - | 38.77M | 32.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 1.04M | 4.47M | 2.98M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 122.78M | 134.48M | 139.69M | 164.13M |
| Operating Income | -122.78M | -133.44M | -135.22M | -161.16M |
| EBITDA | -121.26M | -120.25M | -123.64M | -144.65M |
| Interest Expense | 291.00K | 335.00K | 18.00K | 17.00K |
| Pretax Income | -124.32M | -125.49M | -128.85M | -149.57M |
| Tax Provision | 347.00K | 447.00K | 469.00K | -927.00K |
| Net Income | -124.67M | -125.94M | -129.32M | -148.65M |
| Diluted EPS | -4.52 | -1.32 | -4.73 | -5.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 317.15M | 286.52M | 197.44M | 269.79M |
| Current Assets | 248.71M | 192.54M | 135.51M | 190.66M |
| Cash & Equivalents | 241.04M | 52.55M | 59.14M | 41.69M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 461.77M | 549.23M | 579.96M | 758.07M |
| Current Liabilities | 22.80M | 22.09M | 28.41M | 26.48M |
| Long Term Debt | 4.76M | - | - | - |
| Total Debt | 42.49M | 34.38M | 31.01M | 27.11M |
| Total Equity | -144.62M | -262.71M | -382.53M | -488.28M |
| Shares Outstanding | 47.17M | 47.17M | 47.17M | 47.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -99.84M | -112.73M | -117.47M | -129.47M |
| Investing Cash Flow | -13.03M | -165.02M | 96.78M | -103.94M |
| Financing Cash Flow | 182.72M | 92.08M | 26.98M | 215.65M |
| Capital Expenditure | -13.03M | -5.06M | -764.00K | -1.23M |
| Free Cash Flow | -112.87M | -117.78M | -118.23M | -130.70M |
| Net Change in Cash | 69.85M | -185.67M | 6.29M | -17.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | -12,867.8% | -3,023.8% | -5,415.2% |
| Net Margin % | - | -12,144.5% | -2,891.8% | -4,994.9% |
| ROE % | 86.2% | 47.9% | 33.8% | 30.4% |
| ROCE % | -41.7% | -50.5% | -80.0% | -66.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ODTX
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQc3VZeXpKVDd2ZWVJQ0ZpOTBEMTN1amFOQTVCWTk0ZVEyYllRcjN3djFkOWdwWmNzeXB6QmhuTXNsa2ktN1FDYUszcEZZNzZvdUNNbHVrcDlMUkY2V2VYY3N2WlBEZ19CNEJvNUVUNnh1NWl6SFpyTGhtZ3NKQjRzXw?oc=5" target="_…
Odyssey Therapeutics, Inc (ODTX) Stock Price Today: $18.89 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE9jQzY0LUI5MHdrOC1rYUJnWklCMDJfRFc4UV8yWGQ0VHk2dVVvV2ZsY3czQm14OWlvaGk4NEhXU3FlVjhOX295cGhfU1hlbU1HSlVudTNzdw?oc=5" target="_blank">Odyssey Therapeutics, Inc (ODTX) Stock Price Toda…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFAxeHo3U0cxaWxuREZUa1RqdWtCci05VjcybDdrcGl3U1NlTk56dWQ1S1BHZmhSRUgtNzRycTVDMlQ0eF9McHNUUF85aHBlR1dI?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
ODTX Stock Price and Chart — NASDAQ:ODTX - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9YMTZ0VlFxNXpHYU1XRHQ0b0s1eWhHdjFwNUZNU01TWEV0Wkx1Q2RGaHRqYnNGZWVVZ2QxWUlvNHBLUHZHVURJT3E0MnNxQ094NFNRSFhLRjBDa1ZH?oc=5" target="_blank">ODTX Stock Price and Chart — NASDAQ:ODTX</a…
Odyssey Therapeutics, Inc. (ODTX) Dividend Yield (TTM) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBVUHhRQ0F2Mk8zdm1FaTkyYmJDMjFGQ0RGN3FRUWFpSkQ3Y3ktaWdJbDBweW9yZTBKOExwU3gxMGVUYV8tRmxGYWlRVGVhbEFwZFJuTi0xNnVhZ3BNUzFWR0hieXdfczY2Y2lRbmMxajByWmk1VGtTZg?oc=5" target="_blank">Odyss…
$304M biotech IPO sends Odyssey Therapeutics to Nasdaq May 8 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWWJ5UnVaUEQ0aUxKZGRQbTdXU2MzOUFVV0RseEdoMFRVQzZDQmRNNkltclFEOVFxY0JIakxlQ28zS0Y4MXBka3diZEMtZFFxTWxoUUgtRUlZTy1GOGxJLWZ2MzZFU0w4QzRLZGpNYzQ3eVdxcnRZQkpmMXRaYTNYQ1p0ZkdsQ1A4cGVvZF…
ODTX — Frequently Asked Questions
What is the current share price of ODTX?
As of 2026-08-05 17:25 PDT, ODTX trades at $20.89 on NASDAQ/NYSE. Its 52-week range is $15.56 to $20.89.
What is the market capitalisation of ODTX?
ODTX has a market capitalisation of $985.47M on NASDAQ/NYSE.
What is the P/E ratio of ODTX?
ODTX trades at a trailing price-to-earnings (P/E) ratio of -3.88. Its price-to-book (P/B) ratio is -2.02.
What is the return on equity (ROE) of ODTX?
ODTX has a return on equity (ROE) of 30.44%. Its return on capital employed (ROCE) is -66.23%.
Is ODTX a good stock to buy?
This page provides a data-driven analysis of ODTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.